Pharmaceutical Vilazodone HCl Powder 99% Vilazodone Hydrochloride Intermediate Vilazodone

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Vilazodone
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Vilazodone
• Appearance: White or off-White Solid Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Depression
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 163521-12-8
• Mf: C26h27n5o2
• MW: 477.993
• Density: 1.34
• Melting Point: 203-205 C
• Boiling Point: 745.1 C at 760 Mmhg
• Flash Point: 745.1 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

Pharmaceutical Vilazodone Hcl Powder 99% Vilazodone Hydrochloride Intermediate Vilazodone

Product Description

Product Details

Product Name	Vilazodone
Appearance	White or off-white solid powder
Application	Depression
CAS No.	163521-12-8
MF	C26H27N5O2

Vilazodone is a kind of serotonergic antidepressant developed by Merck KGaA Company.   It is a novel compound with high affinity and selectivity for the 5-hydroxytrptamine (5-HT) transporter and 5-HT (1A) receptors.   It is indicated for the treatment of major depressive disorder (MDD).   It is can be used as an alternative drugs for other kind of antidepressant classes drugs that can't be tolerated by patients.   As a selective serotonin reuptake inhibitor, vilazodone can prevent the serotonin from re-entering into cell bodies, therefore making it remain longer inside the synapse.   Moreover, it has a high selectivity for the serotonin-1A receptor, taking effect as a partial agonist that can simulate the production of serotonin.   These effects result in increased serotonin in the synaptic cleft.   This effect is related to the antidepressant effect of vilazodone in vivo.

Application & Function

It is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.

Specification